Ms. Joy Silver’s criticisms of right-to-try laws are ill-conceived.
When treatments are unavailable, and prognoses are fatal, the best chance to prolong life is to consider all remaining options.
Right-to-try will never reach its potential without deregulation.
Right-to-try, MDMA, and Epidolex provide examples of the power of public opinion to change the scope of government.
FDA regulation holds part of the blame for high drug prices.
On May 30, President Trump signed a bill into law allowing terminally ill patients access to potentially lifesaving drugs before they are approved by the Food and Drug Administration.
Upon deeper inspection, it seems the conventional arguments against right-to-try come up short.
Right-to-try laws only apply to terminally ill patients who have exhausted all other options.
The Goldwater Institute has had great success getting states to pass “Right to Try” laws. Right to Try allows a desperately sick patient to take an experimental new medicine before the FDA has approved it. Since I last wrote about this in May 2014, 31 states have passed Right to Try. Further, U.S. Senator...
Read More »